Key result
Extended-release metoprolol succinate reduced the relative risk of all-cause mortality by 34% versus placebo in patients with chronic heart failure.
Why the study?
Does extended-release metoprolol succinate reduce mortality and morbidity in patients with chronic heart failure?
Does extended-release metoprolol succinate reduce mortality and morbidity in patients with chronic heart failure?
Effect estimate: RR reduction 34%
Extended-release metoprolol succinate provides substantial mortality and morbidity benefits and is well tolerated in patients with symptomatic chronic heart failure.
No takes yet. Share an insight, caveat, or question.
May support mortality reduction in symptomatic chronic HF; leaves open need for updated trials in contemporary populations.
Tangeman et al. (2003) conducted a review in chronic heart failure. Extended-release metoprolol succinate vs. placebo was evaluated on all-cause mortality (RR reduction 34%). Extended-release metoprolol succinate reduced the relative risk of all-cause mortality by 34% versus placebo in patients with chronic heart failure.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: